Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Patient-Reported Outcomes and Medication Adherence in Patients with Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor based approach

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Thromboembolic events related to atrial fibrillation during the COVID-19 epidemic in Denmark

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  • Peter Vibe Rasmussen
  • Frederik Dalgaard
  • Gunnar Hilmar Gislason
  • Axel Brandes
  • Søren Paaske Johnsen
  • Erik Lerkevang Grove
  • Christian Torp-Pedersen
  • Anne-Marie Bloch Münster
  • Marie Schmidt Erikson
  • Jannik Langtved Pallisgaard
  • Paul Blanche
  • Morten Lock Hansen
Vis graf over relationer

AIMS: Patients with atrial fibrillation (AF) treated with oral anticoagulants (OACs) have an increased risk of bleeding including haematuria. In the general population, gross haematuria is associated with urinary tract cancer. Consequently, we aimed to investigate the potential association between gross haematuria and urinary tract cancer in anticoagulated patients with AF.

METHODS AND RESULTS : Using Danish nationwide registers, we included Danish AF patients treated with OACs between 2001 and 2015. Non-parametric estimation and semi-parametric absolute risk regression were used to estimate the absolute risk of urinary tract cancer in patients with and without gross haematuria. We included 125 063 AF patients with a median age of 74 years (interquartile range 65-80) and a majority of males (57%). The absolute risk of gross haematuria 12 months after treatment initiation increased with age ranging from 0.37% [95% confidence interval (CI) 0.31-0.42] to 0.85% (95% CI 0.75-0.96) in the youngest and oldest age groups of ≤70 and >80 years of age, respectively. The 1-year risk of urinary tract cancer after haematuria ranged from 4.2% (95% CI 2.6-6.6) to 6.5% (95% CI 4.6-9.0) for patients in age group >80 and 71-80 years, respectively. Gross haematuria conferred large risk ratios of urinary tract cancer when comparing patients with and without haematuria across all age groups.

CONCLUSION : Gross haematuria was associated with clinically relevant risks of urinary tract cancer in anticoagulated patients with AF. These findings underline the importance of meticulously examining anticoagulated patients with haematuria.

OriginalsprogEngelsk
TidsskriftEuropean heart journal. Cardiovascular pharmacotherapy
Vol/bind7
Udgave nummer5
Sider (fra-til)373-379
Antal sider7
ISSN2055-6837
DOI
StatusUdgivet - 1 sep. 2021

Bibliografisk note

© Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2020. For permissions, please email: journals.permissions@oup.com.

ID: 59856337